Detection of gadolinium deposition in cortical bone with ultrashort echo time T1mapping: an ex vivo study in a rabbit model
- 1 March 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Radiology
- Vol. 31 (3), 1569-1577
- https://doi.org/10.1007/s00330-020-07258-x
Abstract
Objectives To investigate the capacity of ultrashort echo time (UTE) T(1)mapping to non-invasively assess gadolinium deposition in cortical bone after gadolinium-based contrast agent (GBCA) administration. Methods Twenty-eight New Zealand rabbits (male, 3.0-3.5 kg) were randomly allocated into control, macrocyclic, high-dose macrocyclic, and linear GBCA groups (n= 7 for each group), and respectively given daily doses of 0.9 ml/kg bodyweight saline, 0.3 mmol/kg bodyweight gadobutrol, 0.9 mmol/kg bodyweight gadobutrol, and 0.3 mmol/kg bodyweight gadopentetate dimeglumine for five consecutive days per week over a period of 4 weeks. After a subsequent 4 weeks of recovery, the rabbits were sacrificed and their tibiae harvested. T(1)value of cortical bone was measured using a combination of UTE actual flip angle imaging and variable repetition time on a 7T animal scanner. Gadolinium concentration in cortical bone was measured using inductively coupled plasma mass spectrometry (ICP-MS). Pearson's correlation between R(1)value (R-1= 1/T-1) and gadolinium concentration in cortical bone was assessed. Results Bone T(1)values were significantly lower in the lower-dose macrocyclic (329.2 +/- 21.0 ms,p< 0.05), higher-dose macrocyclic (316.8 +/- 21.7 ms,p< 0.01), and linear (296.8 +/- 24.1 ms,p< 0.001) GBCA groups compared with the control group (356.3 +/- 19.4 ms). Gadolinium concentrations measured by ICP-MS in the control, lower-dose macrocyclic, higher-dose macrocyclic, and linear GBCA groups were 0.04 +/- 0.02 mu g/g, 2.60 +/- 0.48 mu g/g, 4.95 +/- 1.17 mu g/g, and 13.62 +/- 1.55 mu g/g, respectively. There was a strong positive correlation between R(1)values and gadolinium concentrations in cortical bone (r= 0.73,p< 0.001). Conclusions These results suggest that UTE T(1)mapping has the potential to provide a non-invasive assessment of gadolinium deposition in cortical bone following GBCA administration.Funding Information
- National Natural Science Foundation of China (81871349, 61671228, 81801653)
- Science and Technology Program of Guangdong (2018B030333001 and 2017B090912006)
This publication has 47 references indexed in Scilit:
- Brain tissue gadolinium retention in pediatric patients after contrast-enhanced magnetic resonance exams: pathological confirmationPediatric Radiology, 2020
- Non-clinical assessment of safety and gadolinium deposition after cumulative administration of gadobenate dimeglumine (MultiHance ® ) to neonatal and juvenile ratsRegulatory Toxicology and Pharmacology, 2018
- Differences in gadolinium retention after repeated injections of macrocyclic MR contrast agents to ratsJournal of Magnetic Resonance Imaging, 2017
- Macrocyclic and Other Non–Group 1 Gadolinium Contrast Agents Deposit Low Levels of Gadolinium in Brain and Bone TissueInvestigative Radiology, 2016
- Self-reported gadolinium toxicity: A survey of patients with chronic symptomsMagnetic Resonance Imaging, 2016
- 25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future PerspectivesAdvances in Therapy, 2016
- High Signal Intensity in Dentate Nucleus on Unenhanced T1-weighted MR Images: Association with Linear versus Macrocyclic Gadolinium Chelate AdministrationRadiology, 2015
- Bone as Target Organ for Metals: The Case of f-ElementsChemical Research in Toxicology, 2012
- Incorporation of excess gadolinium into human bone from medical contrast agentsMetallomics, 2009
- Exposure, metabolism, and toxicity of rare earths and related compounds.Environmental Health Perspectives, 1996